{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:40:00Z","timestamp":1779892800139,"version":"3.53.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Treat-to-target (T2T) approach has improved outcomes in chronic diseases. The aim of this review is to discuss the long-term goals and review the evidence for possible targets that would predict the achievement of these goals for developing a T2T strategy for Beh\u00e7et's syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>There are no trials comparing a tight control strategy to standard care in Beh\u00e7et's syndrome but recent studies suggest better outcomes with earlier use of biologic agents compared with sustained conventional treatment. Fluorescein angiography may be a reliable tool for assessing remission in uveitis as fluorescein angiography findings were shown to predict relapses and long-term visual outcome. Good recanalization on Doppler ultrasonography can be a target for venous involvement as this was the only predictor of relapse. Fecal calprotectin levels were associated with small intestinal and colonic ulcers and may be used as a surrogate for remission of gastrointestinal involvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There are several new treatment modalities that are tried for Beh\u00e7et's syndrome and ongoing work on outcome measures for reliable disease assessment. In order to ensure the wise and efficient use of treatment modalities, development and implementation of T2T strategies are needed through multidisciplinary and multinational efforts that include patient research partners.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000854","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:18:58Z","timestamp":1635466738000},"page":"39-45","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["A treat-to-target approach is needed for Beh\u00e7et's syndrome"],"prefix":"10.1097","volume":"34","author":[{"given":"G\u00fclen","family":"Hatemi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty"},{"name":"Beh\u00e7et's Disease Research Center, Istanbul University-Cerrahpasa Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rdc.2019.07.001","article-title":"Treat to target in rheumatology: a historical account on occasion of the 10th anniversary","volume":"45","author":"Smolen","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.rdc.2019.06.001","article-title":"The \u2018treat to target\u2019 approach to rheumatoid arthritis","volume":"45","author":"Salomon-Escoto","year":"2019","journal-title":"Rheum Dis Clin North Am"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R8-20250526","article-title":"The OMERACT core set of domains for outcome measures in Beh\u00e7et syndrome","author":"Hatemi","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/rheumatology\/kez598","article-title":"Long term follow-up of Beh\u00e7et's syndrome patients treated with cyclophosphamide","volume":"59","author":"Gurcan","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Beh\u00e7et's syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"609148","DOI":"10.3389\/fphar.2021.609148","article-title":"The efficacy of adalimumab as an initial treatment in patients with Beh\u00e7et's retinal vasculitis","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1080\/09273948.2019.1641611","article-title":"The relationship between fluorescein angiography leakage after infliximab therapy and relapse of ocular inflammatory attacks in ocular Beh\u00e7et's disease patients","volume":"28","author":"Shirahama","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40942-021-00318-4","article-title":"Fluorescein angiographic findings and Behcet's disease ocular attack score 24 (BOS24) as prognostic factors for visual outcome in patients with ocular Behcet's disease","volume":"7","author":"Keorochana","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","article-title":"Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients","volume":"91","author":"Seyahi","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"(6 Suppl 102)","key":"R16-20250526","first-page":"92","article-title":"Bronchial artery enlargement may be the cause of recurrent haemoptysis in Beh\u00e7et's syndrome patients with pulmonary artery involvement during follow-up","volume":"34","author":"Esatoglu","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/kez352","article-title":"Clinical course of acute deep vein thrombosis of the legs in Beh\u00e7et's syndrome","volume":"59","author":"Ozguler","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/1751-2980.12965","article-title":"Mucosal healing in intestinal Beh\u00e7et's disease: a systematic review and meta-analysis","volume":"22","author":"Gong","year":"2021","journal-title":"J Dig Dis"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/jgh.14995","article-title":"Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients with Beh\u00e7et disease","volume":"35","author":"Hayashida","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"(6 Suppl 115)","key":"R21-20250526","first-page":"90","article-title":"Faecal but not serum calprotectin levels look promising in predicting active disease in Beh\u00e7et's syndrome patients with gastrointestinal involvement","volume":"36","author":"Esatoglu","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"R22-20250526","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of Apremilast for oral ulcers in Beh\u00e7et's syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N Engl J Med"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"e001525","DOI":"10.1136\/rmdopen-2020-001525","article-title":"Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy","volume":"7","author":"Sundin","year":"2021","journal-title":"RMD Open"},{"issue":"(Suppl 1086)","key":"R25-20250526","first-page":"86","article-title":"Infliximab for uveitis of Beh\u00e7et's syndrome: a trend for earlier initiation","volume":"35","author":"Guzelant","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3899\/jrheum.200300","article-title":"Long-term follow-up and optimization of infliximab in refractory uveitis due to Beh\u00e7et disease: national study of 103 white patients","volume":"48","author":"Mart\u00edn-Varillas","year":"2021","journal-title":"J Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:20:20Z","timestamp":1748294420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000854","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]}}}